AS01B adjuvant mechanisms and CD4 T cell responses

Abstract

AS01B adjuvant induces CD4 T cell responses through a two-phase mechanism involving initial transient inflammatory activation followed by sustained IFN-signaling pathway engagement. Studies demonstrate that AS01B triggers early innate responses including IL-6 and CRP peaking at 24 hours post-vaccination, followed by IFN-γ upregulation and activation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10) after the second dose. This innate activation directly correlates with enhanced CD4+ T cell outcomes, as multi-parametric modeling shows associations between CRP, IL-6, IFN-signaling pathway activation and subsequent CD4 responses. AS01B consistently induces superior CD4 T cell responses compared to AS02A (3.1-fold higher frequencies), AS03 (5.4-fold higher), AS04 (2.8-fold higher), and aluminum adjuvants, with exceptional durability extending 18-36+ months post-vaccination.

The CD4 response polarization induced by AS01B is context-dependent rather than fixed. Protein/AS01B formulations activate PPAR, FcεRI, and TGF-β pathways, inducing Th2/Tfh2-biased responses that correlate with enhanced antibody production and memory B cell frequencies. In contrast, most other AS01B formulations primarily activate IFN-signaling pathways, driving strong Th1 responses characterized by high IFN-γ production. AS01B’s superiority depends on both liposomal delivery and optimal component dosing, as AS01E containing half the MPL/QS-21 produces comparable innate profiles but 2.2-fold lower CD4 responses. The synergistic combination of MPL and QS-21 in liposomes appears critical for maximal CD4 activation.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200 Papers screened using: AS01B Adjuvant Focus, CD4 T Cell Response Measurement, Appropriate Study Type, AS01B Data Availability, CD4 T Cell Data Inclusion, CD4 T Cell Response Focus, AS01B Effect Attribution, Full Publication Status

• n = 200 Papers screened out

• n = 10 Papers included for extraction

Data extraction

We asked a large language model to extract each data column below from each paper. We gave the model the extraction instructions shown below for each column.

Study Context:

• Study population: Healthy human adults
• Antigen used with AS01B: RTS,S antigen
• Study design: Double-blind, randomized trial
• Sample size for AS01B group: Approximately 51 participants

AS01B Mechanisms:

• Specific cytokines induced by AS01B: Interleukin-2, interferon-gamma, tumor necrosis factor-alpha, CD40L

CD4 Responses:

• CD4 T cell proliferation or activation markers: Higher numbers of CSP-specific CD4(+) T cells expressing interleukin-2, interferon-gamma, tumor necrosis factor-alpha, or CD40L.

Key Findings:

• Primary conclusions about AS01B's mechanism of action: Enhances efficacy of RTS,S vaccine with higher efficacy rate compared to AS02A.

• Key findings about AS01B's ability to induce CD4 responses: Higher numbers of CSP-specific CD4(+) T cells and higher ex vivo IFN-gamma ELISPOTs compared to AS02A.

• Novel insights about AS01B compared to other adjuvants: Induces greater CSP-specific immune responses compared to AS02A.